Table Info

Table 1.

List of AGEs studied in cancer so far

Categories of AGEs	AGE modifications identified	References
AGE-modified proteins/DNA	Annexin II Apolipoprotein B100 N²-(1-carboxyethyl)-2’-deoxyguanosine (CEdG)-DNA adducts Collagen type IV Crystallin DNA- and RNA-binding proteins DNA-histone crosslinks Fibrinogen Glycerol-3-phosphate dehydrogenase (G3PDH) HDL Glycated haemoglobin (HbA1C) Heat shock proteins (HSPs) Human serum albumin (HSA) Histone proteins (H1, H2A and H2B) Lactate dehydrogenase (LDH) Prohibitin Transcription factors Splicing factors	[15–21]
Low molecular structures produced during glycation	Argpyrimidine Fructosylysine Imidazole Methylglyoxal (MG) lysine dimer Nε carboxy-methyl lysine (CML) Nε carboxy-ethyl lysine (CEL) Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) Pyrraline Pentosidine	[16, 19, 22, 23]
Unspecified structures formed by alterations with certain glycating agents	Acetaldehyde-derived AGEs Glucose-derived AGEs Glyceraldehyde-derived AGEs Glycoaldehyde-derived AGEs Glyoxal-derived AGEs MG-derived AGEs 3-Deoxyglucosone-derived AGEs	[19, 24–26]

Categories of AGEs

AGE modifications identified

References

AGE-modified proteins/DNA

Annexin II
Apolipoprotein B100
N²-(1-carboxyethyl)-2’-deoxyguanosine (CEdG)-DNA adducts
Collagen type IV
Crystallin
DNA- and RNA-binding proteins
DNA-histone crosslinks
Fibrinogen
Glycerol-3-phosphate dehydrogenase (G3PDH)
HDL
Glycated haemoglobin (HbA1C)
Heat shock proteins (HSPs)
Human serum albumin (HSA)
Histone proteins (H1, H2A and H2B)
Lactate dehydrogenase (LDH)
Prohibitin
Transcription factors
Splicing factors

[15–21]

Low molecular structures produced during glycation

Argpyrimidine
Fructosylysine
Imidazole
Methylglyoxal (MG) lysine dimer
Nε carboxy-methyl lysine (CML)
Nε carboxy-ethyl lysine (CEL)
Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1)
Pyrraline
Pentosidine

[16, 19, 22, 23]

Unspecified structures formed by alterations with certain glycating agents

Acetaldehyde-derived AGEs
Glucose-derived AGEs
Glyceraldehyde-derived AGEs
Glycoaldehyde-derived AGEs
Glyoxal-derived AGEs
MG-derived AGEs
3-Deoxyglucosone-derived AGEs

[19, 24–26]

MG-H1: MG-derived hydroimidazolone

Declarations

Author contributions

GP: Conceptualization, Investigation, Writing—original draft, Validation, Writing—review & editing. SFDP: Validation, Writing—review & editing, Supervision.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Simm A. Protein glycation during aging and in cardiovascular disease. J Proteomics. 2013;92:248–59. [DOI] [PubMed]

Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14:453. [DOI] [PubMed] [PMC]

Lin JA, Wu CH, Lu CC, Hsia SM, Yen GC. Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: an emerging biological factor in cancer onset and progression. Mol Nutr Food Res. 2016;60:1850–64. [DOI] [PubMed]

Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012;42:1205–20. [DOI] [PubMed]

Ahmad S, Moinuddin, Shahab U, Habib S, Salman Khan M, Alam K, et al. Glycoxidative damage to human DNA: neo-antigenic epitopes on DNA molecule could be a possible reason for autoimmune response in type 1 diabetes. Glycobiology. 2014;24:281–91. [DOI] [PubMed]

Nowotny K, Jung T, Grune T, Höhn A. Accumulation of modified proteins and aggregate formation in aging. Exp Gerontol. 2014;57:122–31. [DOI] [PubMed]

Arasteh A, Farahi S, Habibi-Rezaei M, Moosavi-Movahedi AA. Glycated albumin: an overview of the in vitro models of an in vivo potential disease marker. J Diabetes Metab Disord. 2014;13:49. [DOI] [PubMed] [PMC]

Juranek JK, Daffu GK, Wojtkiewicz J, Lacomis D, Kofler J, Schmidt AM. Receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis. Front Cell Neurosci. 2015;9:485. [DOI] [PubMed] [PMC]

Monacelli F, Borghi R, Pacini D, Serrati C, Traverso N, Odetti P. Pentosidine determination in CSF: a potential biomarker of Alzheimer’s disease? Clin Chem Lab Med. 2014;52:117–20. [DOI] [PubMed]

10.

Nedić O, Rattan SI, Grune T, Trougakos IP. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res. 2013;47:28–38. [DOI] [PubMed]

11.

Padayatti PS, Ng AS, Uchida K, Glomb MA, Nagaraj RH. Argpyrimidine, a blue fluorophore in human lens proteins: high levels in brunescent cataractous lenses. Invest Ophthalmol Vis Sci. 2001;42:1299–304. [PubMed]

12.

Palanissami G, Paul SFD. RAGE and its ligands: molecular interplay between glycation, inflammation, and hallmarks of cancer—a review. Horm Cancer. 2018;9:295–325. [DOI] [PubMed] [PMC]

13.

Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1–14. [DOI] [PubMed] [PMC]

14.

Sadowska-Bartosz I, Bartosz G. Prevention of protein glycation by natural compounds. Molecules. 2015;20:3309–34. [DOI] [PubMed] [PMC]

15.

Tamae D, Lim P, Wuenschell GE, Termini J. Mutagenesis and repair induced by the DNA advanced glycation end product N²-1-(carboxyethyl)-2’-deoxyguanosine in human cells. Biochemistry. 2011;50:2321–9. [DOI] [PubMed] [PMC]

16.

Korwar AM, Bhonsle HS, Chougale AD, Kote SS, Gawai KR, Ghole VS, et al. Analysis of AGE modified proteins and RAGE expression in HER2/neu negative invasive ductal carcinoma. Biochem Biophys Res Commun. 2012;419:490–4. [DOI] [PubMed]

17.

Sanghvi VR, Leibold J, Mina M, Mohan P, Berishaj M, Li Z, et al. The oncogenic action of NRF2 depends on de-glycation by fructosamine-3-kinase. Cell. 2019;178:807–19.E21. [DOI] [PubMed] [PMC]

18.

Pouliquen DL, Boissard A, Coqueret O, Guette C. Biomarkers of tumor invasiveness in proteomics (review). Int J Oncol. 2020;57:409–32. [DOI] [PubMed] [PMC]

19.

Kuzan A. Toxicity of advanced glycation end products (review). Biomed Rep. 2021;14:46. [DOI] [PubMed] [PMC]

20.

Rehman S, Aatif M, Rafi Z, Khan MY, Shahab U, Ahmad S, et al. Effect of non-enzymatic glycosylation in the epigenetics of cancer. Semin Cancer Biol. 2022;83:543–55. [DOI] [PubMed]

21.

Mir AR, Habib S, Uddin M. Recent advances in histone glycation: emerging role in diabetes and cancer. Glycobiology. 2021;31:1072–9. [DOI] [PubMed]

22.

Nass N, Ignatov A, Andreas L, Weißenborn C, Kalinski T, Sel S. Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases. Histochem Cell Biol. 2017;147:625–34. [DOI] [PubMed]

23.

Aglago EK, Schalkwijk CG, Freisling H, Fedirko V, Hughes DJ, Jiao L, et al. Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. Carcinogenesis. 2021;42:705–13. [DOI] [PubMed] [PMC]

24.

Deng R, Wu H, Ran H, Kong X, Hu L, Wang X, et al. Glucose-derived AGEs promote migration and invasion of colorectal cancer by up-regulating Sp1 expression. Biochim Biophys Acta Gen Subj. 2017;1861:1065–74. [DOI] [PubMed]

25.

Sharaf H, Matou-Nasri S, Wang Q, Rabhan Z, Al-Eidi H, Al Abdulrahman A, et al. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim Biophys Acta. 2015;1852:429–41. [DOI] [PubMed]

26.

Coluccio ML, Presta I, Greco M, Gervasi R, La Torre D, Renne M, et al. Microenvironment molecular profile combining glycation adducts and cytokines patterns on secretome of short-term blood-derived cultures during tumour progression. Int J Mol Sci. 2020;21:4711. [DOI] [PubMed] [PMC]

27.

Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17. [DOI] [PubMed] [PMC]

28.

Hudson BI, Kalea AZ, del Mar Arriero M, Harja E, Boulanger E, D’Agati V, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42*. J Biol Chem. 2008;283:34457–68. [DOI] [PubMed] [PMC]

29.

Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling☆. Redox Biol. 2014;2:411–29. [DOI] [PubMed] [PMC]

30.

Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25:2185–97. [DOI] [PubMed]

31.

Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28. [DOI] [PubMed] [PMC]

32.

Rojas A, Añazco C, González I, Araya P. Extracellular matrix glycation and receptor for advanced glycation end-products activation: a missing piece in the puzzle of the association between diabetes and cancer. Carcinogenesis. 2018;39:515–21. [DOI] [PubMed]

33.

Kim HM, Kim S, Sim J, Ma BS, Yong I, Jo Y, et al. Glycation-mediated tissue-level remodeling of brain meningeal membrane by aging. Aging Cell. 2023;22:e13805. [DOI] [PubMed] [PMC]

34.

Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR, et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene. 2014;33:567–77. [DOI] [PubMed] [PMC]

35.

Krisanits B, Randise JF, Burton CE, Findlay VJ, Turner DP. Chapter three - Pubertal mammary development as a “susceptibility window” for breast cancer disparity. Adv Cancer Res. 2020;146:57–82. [DOI] [PubMed] [PMC]

36.

Krisanits B. The impact of sugar derived metabolites (AGEs) on pubertal mammary gland development [dissertation]. Medical University of South Carolinal; 2017.

37.

Randise JF, Krisanits BA, Nogueira LM, Helke KL, Campbell T, Findlay VJ, et al. Abstract 2234: Dietary-AGE ingestion during puberty modifies the breast microenvironment to alter mammary gland development: linking diet, development and breast cancer risk. Cancer Res. 2018;78:2234. [DOI]

38.

Frye CC, Krisanits BA, Schuster R, Randise J, Nogueira LM, Helke K, et al. Abstract C029: Consumption of dietary AGEs during puberty and increased breast cancer risk: A link between lifestyle and cancer disparity. Cancer Epidemiol Biomarkers Prev. 2020;29:C029. [DOI]

39.

Krisanits BA, Woods P, Nogueira LM, Woolfork DD, Lloyd CE, Baldwin A, et al. Non-enzymatic glycoxidation linked with nutrition enhances the tumorigenic capacity of prostate cancer epithelia through AGE mediated activation of RAGE in cancer associated fibroblasts. Transl Oncol. 2022;17:101350. [DOI] [PubMed] [PMC]

40.

Foster D, Spruill L, Walter KR, Nogueira LM, Fedarovich H, Turner RY, et al. AGE metabolites: a biomarker linked to cancer disparity? Cancer Epidemiol Biomarkers Prev. 2014;23:2186–91. [DOI] [PubMed] [PMC]

41.

Peng Y, Liu F, Qiao Y, Wang P, Du H, Si C, et al. Genetically modified circulating levels of advanced glycation end-products and their soluble receptor (AGEs-RAGE axis) with risk and mortality of breast cancer. Cancers (Basel). 2022;14:6124. [DOI] [PubMed] [PMC]

42.

Aglago EK, Mayén AL, Knaze V, Freisling H, Fedirko V, Hughes DJ, et al. Dietary advanced glycation end-products and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Nutrients. 2021;13:3132. [DOI] [PubMed] [PMC]

43.

Peterson LL, Omofuma O, Turner DP, Merchant A, Zhang J, Neuhouser ML, et al. Dietary advanced glycation end products (AGEs) and breast cancer mortality in the women’s health initiative (WHI). J Clin Oncol. 2020;38:1570. [DOI]

44.

Omofuma OO. Dietary advanced glycation end-products (ages) and breast cancer risk and survival [dissertation]. University of South Carolina; 2019. [DOI] [PubMed] [PMC]

45.

Pan S, Guan Y, Ma Y, Cui Q, Tang Z, Li J, et al. Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling. BMJ Open Diabetes Res Care. 2022;10:e002697. [DOI] [PubMed] [PMC]

46.

Felicetti F, Aimaretti E, Dal Bello F, Gatti F, Godono A, Saba F, et al. Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: a possible role in the onset of late complications. Free Radic Biol Med. 2022;178:76–82. [DOI] [PubMed]

47.

Foussard N, Larroumet A, Rigo M, Mohammedi K, Baillet-Blanco L, Poupon P, et al. Skin autofluorescence predicts cancer in subjects with type 2 diabetes. BMJ Open Diabetes Res Care. 2021;9:e001312. [DOI] [PubMed] [PMC]

48.

Zheng Q, Omans ND, Leicher R, Osunsade A, Agustinus AS, Finkin-Groner E, et al. Reversible histone glycation is associated with disease-related changes in chromatin architecture. Nat Commun. 2019;10:1289. [DOI] [PubMed] [PMC]

49.

Scumaci D, Olivo E, Fiumara CV, La Chimia M, De Angelis MT, Mauro S, et al. DJ-1 proteoforms in breast cancer cells: the escape of metabolic epigenetic misregulation. Cells. 2020;9:1968. [DOI] [PubMed] [PMC]

50.

Choi J, Kim DH, Jung WH, Koo JS. Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res. 2013;15:R78. [DOI] [PubMed] [PMC]

51.

Vikramdeo KS, Sharma A, Anand S, Sudan SK, Singh S, Singh AP, et al. Mitochondrial alterations in prostate cancer: roles in pathobiology and racial disparities. Int J Mol Sci. 2023;24:4482. [DOI] [PubMed] [PMC]

52.

Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, Hall JA, et al.; Cancer Research UK and Cancer Therapeutics CRC Australia Metastasis Working Group. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol. 2019;16:185–204. [DOI] [PubMed] [PMC]

53.

Meghnani V, Vetter SW, Leclerc E. RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. Biochim Biophys Acta. 2014;1842:1017–27. [DOI] [PubMed]

54.

McCann C, Kerr EM. Metabolic reprogramming: a friend or foe to cancer therapy? Cancers (Basel). 2021;13:3351. [DOI] [PubMed] [PMC]

55.

Bronowicka-Szydełko A, Kotyra Ł, Lewandowski Ł, Gamian A, Kustrzeba-Wójcicka I. Role of advanced glycation end-products and other ligands for AGE receptors in thyroid cancer progression. J Clin Med. 2021;10:4084. [DOI] [PubMed] [PMC]

56.

Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, et al. RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Res. 2015;75:974–85. [DOI] [PubMed] [PMC]

57.

Sherbet GV. Molecular approach to cancer management. 1st ed. Elsevier; 2017. [DOI]

58.

Pruitt K. Molecular and cellular changes in the cancer cell. In: Pruitt K, editor. Progress in molecular biology and translational science. Burlington: Academic Press; 2016. pp. 1–602. [DOI]

59.

Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signaling to promote cancer. Mol Cell Biochem. 2021;476:585–98. [DOI] [PubMed]

60.

Maksimovic I, David Y. Non-enzymatic covalent modifications as a new chapter in the histone code. Trends Biochem Sci. 2021;46:718–30. [DOI] [PubMed] [PMC]

61.

Guvatova ZG, Borisov PV, Alekseev AA, Moskalev AA. Age-related changes in extracellular matrix. Biochemistry (Mosc). 2022;87:1535–51. [DOI] [PubMed]

62.

Santolla MF, Talia M, Cirillo F, Scordamaglia D, De Rosis S, Spinelli A, et al. The AGEs/RAGE transduction signaling prompts IL-8/CXCR1/2-mediated interaction between cancer-associated fibroblasts (CAFs) and breast cancer cells. Cells. 2022;11:2402. [DOI] [PubMed] [PMC]

63.

Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis. 2014;5:e1065. [DOI] [PubMed] [PMC]

64.

Kang R, Tang D, Loze MT, Zeh I, Herbert HJ. Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy. 2011;7:91–3. [DOI] [PubMed]

65.

Kang R, Loux T, Tang D, Schapiro NE, Vernon P, Livesey KM, et al. The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A. 2012;109:7031–6. [DOI] [PubMed] [PMC]

66.

Swami P, Radhakrishnan P, Crawford A, Patil P, Shin S, Caffrey T, et al. Combination of RAGE inhibitors and gemcitabine impedes tumor growth by reducing autophagy and facilitating apoptosis in pancreatic cancer. FASEB J. 2019;33:674.19. [DOI]

67.

Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010;17:666–76. [DOI] [PubMed] [PMC]

68.

Galligan JJ, Wepy JA, Streeter MD, Kingsley PJ, Mitchener MM, Wauchope OR, et al. Methylglyoxal-derived posttranslational arginine modifications are abundant histone marks. Proc Natl Acad Sci U S A. 2018;115:9228–33. [DOI] [PubMed] [PMC]

69.

Ahmad S, Moinuddin, Dixit K, Shahab U, Alam K, Ali A. Genotoxicity and immunogenicity of DNA-advanced glycation end products formed by methylglyoxal and lysine in presence of Cu²⁺. Biochem Biophys Res Commun. 2011;407:568–74. [DOI] [PubMed]

70.

Sakasai-Sakai A, Takata T, Takino JI, Takeuchi M. Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death. Sci Rep. 2017;7:14282. [DOI] [PubMed] [PMC]

71.

Lee C, An D, Park J. Hyperglycemic memory in metabolism and cancer. Horm Mol Biol Clin Investig. 2016;26:77–85. [DOI] [PubMed]

72.

Perrone A, Giovino A, Benny J, Martinelli F. Advanced glycation end products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects. Oxid Med Cell Longev. 2020;2020:3818196. [DOI] [PubMed] [PMC]

73.

Zhou L, Wang W, Yang C, Zeng T, Hu M, Wang X, et al. GADD45a promotes active DNA demethylation of the MMP-9 promoter via base excision repair pathway in AGEs-treated keratinocytes and in diabetic male rat skin. Endocrinology. 2018;159:1172–86. [DOI] [PubMed]

74.

Martinez-Outschoorn UE, Curry JM, Ko YH, Lin Z, Tuluc M, Cognetti D, et al. Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4. Cell Cycle. 2013;12:2580–97. [DOI] [PubMed] [PMC]

75.

Teissier T, Boulanger É. The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. Biogerontology. 2019;20:279–301. [DOI] [PubMed]

76.

Rossi F, Di Paola A, Pota E, Argenziano M, Di Pinto D, Marrapodi MM, et al. Biological aspects of inflamm-aging in childhood cancer survivors. Cancers (Basel). 2021;13:4933. [DOI] [PubMed] [PMC]

77.

Vella V, Lappano R, Bonavita E, Maggiolini M, Clarke RB, Belfiore A, et al. Insulin/IGF axis and the receptor for advanced glycation end products: role in meta-inflammation and potential in cancer therapy. Endocr Rev. 2023;44:693–723. [DOI] [PubMed] [PMC]

78.

Muoio MG, Talia M, Lappano R, Sims AH, Vella V, Cirillo F, et al. Activation of the S100A7/RAGE pathway by IGF-1 contributes to angiogenesis in breast cancer. Cancers (Basel). 2021;13:621. [DOI] [PubMed] [PMC]

79.

Palati S, Pratibha R, Saravanan S. Receptors of advanced glycation end products in oral squamous cell carcinoma: a systematic review. Tumor Discovery. 2023;2:244. [DOI]

80.

Garay-Sevilla ME, Gomez-Ojeda A, González I, Luévano-Contreras C, Rojas A. Contribution of RAGE axis activation to the association between metabolic syndrome and cancer. Mol Cell Biochem. 2021;476:1555–73. [DOI] [PubMed]

81.

Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266:37–52. [DOI] [PubMed] [PMC]

82.

Hubert P, Roncarati P, Demoulin S, Pilard C, Ancion M, Reynders C, et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. J Immunother Cancer. 2021;9:e001966. [DOI] [PubMed] [PMC]

83.

Tanuma SI, Oyama T, Okazawa M, Yamazaki H, Takao K, Sugita Y, et al. A dual anti-inflammatory and anti-proliferative 3-styrylchromone derivative synergistically enhances the anti-cancer effects of DNA-damaging agents on colon cancer cells by targeting HMGB1-RAGE-ERK1/2 signaling. Int J Mol Sci. 2022;23:3426. [DOI] [PubMed] [PMC]

84.

Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol. 2020;10:397. [DOI] [PubMed] [PMC]

85.

Geicu OI, Stanca L, Voicu SN, Dinischiotu A, Bilteanu L, Serban AI, et al. Dietary AGEs involvement in colonic inflammation and cancer: insights from an in vitro enterocyte model. Sci Rep. 2020;10:2754. [DOI] [PubMed] [PMC]

86.

Lai SWT, Lopez Gonzalez EJ, Zoukari T, Ki P, Shuck SC. Methylglyoxal and its adducts: induction, repair, and association with disease. Chem Res Toxicol. 2022;35:1720–46. [DOI] [PubMed] [PMC]

87.

Schildhauer P, Selke P, Scheller C, Strauss C, Horstkorte R, Leisz S, et al. Glycation leads to increased invasion of glioblastoma cells. Cells. 2023;12:1219. [DOI] [PubMed] [PMC]

88.

van Heijst JW, Niessen HW, Hoekman K, Schalkwijk CG. Advanced glycation end products in human cancer tissues: detection of N^ε‐(carboxymethyl) lysine and argpyrimidine. Ann N Y Acad Sci. 2005;1043:725–33. [DOI] [PubMed]

89.

Rojas A, Schneider I, Lindner C, Gonzalez I, Morales MA. The RAGE/multiligand axis: a new actor in tumor biology. Biosci Rep. 2022;42:BSR20220395. [DOI] [PubMed] [PMC]

90.

Burgueño JF, Abreu MT. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat Rev Gastroenterol Hepatol. 2020;17:263–78. [DOI] [PubMed]

91.

Reddy VP, Aryal P, Darkwah EK. Advanced glycation end products in health and disease. Microorganisms. 2022;10:1848. [DOI] [PubMed] [PMC]

92.

Wu C, Du X, Tang L, Wu J, Zhao W, Guo X, et al. Schistosoma japonicum SjE16.7 protein promotes tumor development via the receptor for advanced glycation end products (RAGE). Front Immunol. 2020;11:1767. [DOI] [PubMed] [PMC]

93.

Aschner M, Skalny AV, Gritsenko VA, Kartashova OL, Santamaria A, Rocha JB, et al. Role of gut microbiota in the modulation of the health effects of advanced glycation end‑products (review). Int J Mol Med. 2023;51:44. [DOI] [PubMed] [PMC]

94.

Qu W, Yuan X, Zhao J, Zhang Y, Hu J, Wang J, et al. Dietary advanced glycation end products modify gut microbial composition and partially increase colon permeability in rats. Mol Nutr Food Res. 2017;61:1700118. [DOI] [PubMed]

95.

Wang J, Cai W, Yu J, Liu H, He S, Zhu L, et al. Dietary advanced glycation end products shift the gut microbiota composition and induce insulin resistance in mice. Diabetes Metab Syndr Obes. 2022;15:427–37. [DOI] [PubMed] [PMC]

96.

Phuong-Nguyen K, McNeill BA, Aston-Mourney K, Rivera LR. Advanced glycation end-products and their effects on gut health. Nutrients. 2023;15:405. [DOI] [PubMed] [PMC]

97.

Thekkekkara D, Manjula SN, Mishra N, Bhatt S, Shilpi S. Synbiotics in the management of breast cancer. In: Mishra N, Bhatt S, Paudel KR, M Hansbro P, Dua K, editors. Synbiotics for the management of cancer. Singapore: Springer Nature Singapore; 2023. pp. 289–304. [DOI]

98.

van Dongen KCW, Linkens AMA, Wetzels SMW, Wouters K, Vanmierlo T, van de Waarenburg MP, et al. Dietary advanced glycation endproducts (AGEs) increase their concentration in plasma and tissues, result in inflammation and modulate gut microbial composition in mice; evidence for reversibility. Food Res Int. 2021;147:110547. [DOI] [PubMed]

99.

Fournet M, Bonté F, Desmoulière A. Glycation damage: a possible hub for major pathophysiological disorders and aging. Aging Dis. 2018;9:880–900. [DOI] [PubMed] [PMC]

100.

Hause F, Schlote D, Simm A, Hoffmann K, Santos AN. Accumulation of glycated proteins suggesting premature ageing in lamin B receptor deficient mice. Biogerontology. 2018;19:95–100. [DOI] [PubMed]

101.

Kim CS, Park S, Kim J. The role of glycation in the pathogenesis of aging and its prevention through herbal products and physical exercise. J Exerc Nutrition Biochem. 2017;21:55–61. [DOI] [PubMed] [PMC]

102.

Ramasamy R, Vannucci SJ, Yan SSD, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005;15:16R–28R. [DOI] [PubMed]

103.

Son M, Chung WJ, Oh S, Ahn H, Choi CH, Hong S, et al. Age dependent accumulation patterns of advanced glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands differ in the liver, kidney, and skeletal muscle. Immun Ageing. 2017;14:12. [DOI] [PubMed] [PMC]

104.

Greenwood H, Bartlett DB. Meeting report: British Society for Research on Ageing (BSRA) annual scientific meeting 2012, Aston University, Birmingham, 3rd to 4th July 2012. Longev Healthspan. 2013;2:6. [DOI] [PubMed] [PMC]

105.

Alavez S, Vantipalli MC, Zucker DJ, Klang IM, Lithgow GJ. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature. 2011;472:226–9. [DOI] [PubMed] [PMC]

106.

Li Y, Peng Y, Shen Y, Zhang Y, Liu L, Yang X. Dietary polyphenols: regulate the advanced glycation end products-RAGE axis and the microbiota-gut-brain axis to prevent neurodegenerative diseases. Crit Rev Food Sci Nutr. 2022;[Epub ahead of print]. [DOI] [PubMed]

107.

Song Q, Liu J, Dong L, Wang X, Zhang X. Novel advances in inhibiting advanced glycation end product formation using natural compounds. Biomed Pharmacother. 2021;140:111750. [DOI] [PubMed]

108.

Dariya B, Nagaraju GP. Advanced glycation end products in diabetes, cancer and phytochemical therapy. Drug Discov Today. 2020;25:1614–23. [DOI] [PubMed]

109.

Palanissami G, Paul SFD, inventor; Sri Ramachandra university, assignee. A novel synergistic pharmaceutical formulation exhibiting anti-cancer activity. India patent 201741034218 A. 2017 Nov 17.

110.

Jia W, Guo A, Zhang R, Shi L. Mechanism of natural antioxidants regulating advanced glycosylation end products of Maillard reaction. Food Chem. 2022;404:134541. [DOI] [PubMed]

111.

Knörlein A, Xiao Y, David Y. Leveraging histone glycation for cancer diagnostics and therapeutics. Trends Cancer. 2023;9:410–20. [DOI] [PubMed]

112.

Ko SY, Ko HA, Shieh TM, Chi TC, Chen HI, Chen YT, et al. Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncol Lett. 2017;13:3328–34. [DOI] [PubMed] [PMC]

113.

Ko SY, Ko HA, Shieh TM, Chang WC, Chen HI, Chang SS, et al. Cell migration is regulated by AGE-RAGE interaction in human oral cancer cells in vitro. PLoS One. 2014;9:e110542. [DOI] [PubMed] [PMC]

114.

Siddhartha VT, Pindiprolu SKSS, Chintamaneni PK, Tummala S, Nandha Kumar S. RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies. Artif Cells Nanomed Biotechnol. 2018;46:387–97. [DOI] [PubMed]

115.

Chaudhuri A, Kumar DN, Dehari D, Singh S, Kumar P, Bolla PK, et al. Emergence of nanotechnology as a powerful cavalry against triple-negative breast cancer (TNBC). Pharmaceuticals (Basel). 2022;15:542. [DOI] [PubMed] [PMC]

116.

Konopka CJ, Woźniak M, Hedhli J, Siekierzycka A, Skokowski J, Pęksa R, et al. Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:2562–76. [DOI] [PubMed]

117.

Zhang IY, Liu S, Zhang L, Liang R, Fang Q, Zhao J, et al. RAGE Ablation attenuates glioma progression and enhances tumor immune responses by suppressing galectin-3 expression. Neuro Oncol. 2023;25:886–98. [DOI] [PubMed]

118.

Lan CY, Chen SY, Kuo CW, Lu CC, Yen GC. Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells. J Food Drug Anal. 2019;27:887–96. [DOI] [PubMed] [PMC]

119.

Swami P, Caffrey T, Radhakrishnan P, Shin S, Patil P, Crawford A, et al. Combination of RAGE inhibitors and gemcitabine to mitigate chemo‐resistance in pancreatic cancer. FASEB J. 2018;32:835.7. [DOI]

120.

Healey GD, Pan-Castillo B, Garcia-Parra J, Davies J, Roberts S, Jones E, et al. Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. J Immunother Cancer. 2019;7:280. [DOI] [PubMed] [PMC]

121.

Howard D, Garcia-Parra J, Healey GD, Amakiri C, Margarit L, Francis LW, et al. Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus. 2016;6:20160054. [DOI] [PubMed] [PMC]

122.

Chhipa AS, Borse SP, Baksi R, Lalotra S, Nivsarkar M. Targeting receptors of advanced glycation end products (RAGE): Preventing diabetes induced cancer and diabetic complications. Pathol Res Pract. 2019;215:152643. [DOI] [PubMed]

123.

Li Y, Wang J, Zhong S, Li J, Du W. Scutellarein inhibits the development of colon cancer via CDC4‑mediated RAGE ubiquitination. Int J Mol Med. 2020;45:1059–72. [DOI] [PubMed] [PMC]

124.

El‑Far AHAM, Munesue S, Harashima A, Sato A, Shindo M, Nakajima S, et al. In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system. Oncol Lett. 2018;15:4627–34. [DOI] [PubMed] [PMC]

125.

Dexamethasone and azeliragon for management of post-resection cerebral edema in patients with glioblastoma. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT05773664

126.

Study of effect of azeliragon in patients refractory to first-line metastatic pancreatic cancer. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT05766748

127.

RAGE inhibition to decrease therapy cardiotoxicity in women with early breast cancer (RAGE). Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT05256745

128.

CX-01 combined with azacitidine in the treatment of relapsed or refractory myelodysplastic syndrome and acute myeloid leukemia. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT02995655

129.

Phase I assay-guided trial of anti-inflammatory phytochemicals in patients with advanced cancer. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT01820299

130.

Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT03644212

131.

DPP-IV inhibitors underlying mechanism of cancer in diabetic patients. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT01588587

132.

Dietary advanced glycation end products, inflammation and oxidative stress in breast cancer patients. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT04716764

133.

A low AGE (advanced glycation end-product) dietary intervention for breast cancer survivors. Source: National Library of Medicine; [cited 2023 Aug 24]. Available from: https://www.clinicaltrials.gov/study/NCT05265715

134.

Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. 2017;36:1559–72. [DOI] [PubMed]

135.

El-Far AH, Sroga G, Jaouni SKA, Mousa SA. Role and mechanisms of RAGE-ligand complexes and RAGE-inhibitors in cancer progression. Int J Mol Sci. 2020;21:3613. [DOI] [PubMed] [PMC]

136.

Papale M, Buccarelli M, Mollinari C, Russo MA, Pallini R, Ricci-Vitiani L, et al. Hypoxia, inflammation and necrosis as determinants of glioblastoma cancer stem cells progression. Int J Mol Sci. 2020;21:2660. [DOI] [PubMed] [PMC]

137.

Garza-Campos A, Prieto-Correa JR, Domínguez-Rosales JA, Hernández-Nazará ZH. Implications of receptor for advanced glycation end products for progression from obesity to diabetes and from diabetes to cancer. World J Diabetes. 2023;14:977–94. [DOI] [PubMed] [PMC]

138.

Drake LR, Scott PJH. Targeted nanoparticles for multimodal imaging of the receptor for advanced glycation end-products. Theranostics. 2018;8:6352–4. [DOI] [PubMed] [PMC]

139.

Healey GD, Frostell A, Fagge T, Gonzalez D, Conlan RS. A RAGE-targeted antibody-drug conjugate: surface plasmon resonance as a platform for accelerating effective ADC design and development. Antibodies (Basel). 2019;8:7. [DOI] [PubMed] [PMC]

140.

Faruqui T, Khan MS, Akhter Y, Khan S, Rafi Z, Saeed M, et al. RAGE inhibitors for targeted therapy of cancer: a comprehensive review. Int J Mol Sci. 2022;24:266. [DOI] [PubMed] [PMC]

141.

Shen Y, Xu Z, Sheng Z. Ability of resveratrol to inhibit advanced glycation end product formation and carbohydrate-hydrolyzing enzyme activity, and to conjugate methylglyoxal. Food Chem. 2017;216:153–60. [DOI] [PubMed]